Loading organizations...
Key people at Stallergenes Greer.
Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products. The company focuses on creating therapeutic solutions that address the underlying causes of various allergic conditions, utilizing a precise scientific approach to develop targeted treatments for patients worldwide. This includes a portfolio of products designed to manage conditions such as respiratory allergies and reactions to hymenoptera venom.
The company, Stallergenes Greer, was established in 2015 through the merger of two established entities: Stallergenes and Greer Laboratories Inc. Stallergenes originated in 1962, founded by Institut Mérieux in Europe, contributing a strong legacy of pharmaceutical innovation. Greer Laboratories Inc. was founded significantly earlier in 1904 by Mrs. N.B. Greer in the United States, building foundational expertise in allergy solutions. The strategic combination integrated more than a century of collective experience and research in the allergy field.
Stallergenes Greer’s products are used by individuals experiencing a range of allergic diseases, seeking lasting relief and improved quality of life. The company maintains a vision focused on enhancing patient care by providing advanced and accessible allergen immunotherapy. Through ongoing research and development, Stallergenes Greer aims to lead in redefining how allergies are diagnosed and treated, ultimately striving for a world where people are free from the burden of allergy.
Key people at Stallergenes Greer.
Stallergenes Greer is a Swiss biopharmaceutical company specializing in the diagnosis and treatment of allergies through allergen immunotherapy (AIT), combining over 120 years of expertise from its predecessor companies. It develops and commercializes a broad portfolio of products including sublingual drops and tablets (e.g., Staloral, Oralair, Actair), subcutaneous injections (e.g., Alustal/Albey), oral immunotherapy for peanut allergies (Palforzia), allergen extracts, veterinary products, and testing supplies, serving patients with respiratory and food allergies worldwide via healthcare professionals.[1][2][4] Headquartered in Baar, Switzerland, with manufacturing in Europe, the US, and Canada, it employs 1,129 people across 21 countries (44 including distribution) and operates as a fully integrated global leader in AIT, owned by B-Flexion (formerly Waypoint Capital), a family-led investment firm focused on life sciences.[1][2]
The company addresses the growing global allergy burden by providing innovative, safe treatments that desensitize patients to allergens, improving quality of life through various administration modes.[2][4] Its growth stems from operational efficiencies, market share recovery, and investments in production capacity, as seen in 2019 financial improvements and expanded facilities.[6]
Stallergenes Greer traces its roots to two pioneering entities in allergy care. Greer Laboratories was founded in 1904 by R.T. Greer in the US as a collector of source materials like pollens, herbs, and roots, building expertise in allergen extracts over a century.[1][2] Stallergenes was established in 1962 in France by Institut Mérieux, focusing on innovation in AIT and desensitization therapies.[1][2]
The companies merged in 2015 to form Stallergenes Greer, uniting Greer's US manufacturing and extract prowess with Stallergenes' European R&D in sublingual and other AIT formats, creating a global powerhouse.[1][2][5] Previously, Stallergenes was owned by Wendel Group from 1993-2010, during which revenues grew 10x, establishing it as the world AIT leader before sale to the Bertarelli family's Ares Life Sciences (now under B-Flexion/Waypoint, full ownership by 2019).[3][6] This merger and ownership shift marked a pivotal moment, enabling delisting from the Paris stock exchange and a focus on long-term growth under Ernesto Bertarelli's chairmanship.[1][2][6]
Stallergenes Greer rides the rising tide of allergy prevalence—estimated at billions globally per EAACI data—driven by environmental, lifestyle, and urbanization factors, positioning AIT as a disease-modifying alternative to symptom management.[1][2] Its timing leverages biotech advances in immunotherapy, expanding from respiratory (e.g., grass/ragweed) to food allergies like peanuts, amid regulatory approvals and demand for non-invasive options like sublingual/oral formats.[2][6]
Market forces favor it through aging populations, climate-driven pollen surges, and post-merger scale, enabling competition with big pharma while influencing the ecosystem via manufacturing leadership, physician education, and supply reliability—critical in a fragmented allergy field.[1][4] As a private life sciences player under B-Flexion, it shapes biotech by demonstrating sustainable growth in niche therapeutics, inspiring similar consolidations.[2][3]
Stallergenes Greer is primed for expansion through R&D in new AIT platforms, capacity ramps, and geographic push, building on 2019's turnaround with regained market share and operational excellence.[6] Trends like personalized medicine, AI-driven diagnostics, and oral/food AIT approvals will propel it, especially as B-Flexion fuels life sciences investments.[2]
Its influence may evolve toward dominating global AIT supply amid allergy epidemics, potentially via acquisitions or novel therapies, solidifying its role as the century-spanning leader that merged legacies to treat millions—delivering on the promise of a healthier, allergy-resilient world.[1][2][4]
